The KRASG12C protein product is an attractive, yet challenging, target for small molecule inhibition. One option for therapeutic intervention is to design small molecule ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12. In order to better understand the cellular off-target interactions of <b>Compound 1</b>, a covalent KRASG12C inhibitor, we have completed a series of complementary chemical proteomics experiments in H358 cells. A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C. In addition, the thiol reactive probes allowed us to profile potential off-target interactions of <b>Compound 1</b> with ove...
Medical community and pharmaceutical companies are currently facing a dire need for discovery and id...
Most small-molecule probes and drugs alter cell circuitry by interacting with 1 or more proteins. A ...
Targeted covalent inhibitor design is gaining increasing interest and acceptance. A typical covalent...
Covalent inhibitors have numerous applications as drugs, as tools for drug discovery, and as probes ...
Our laboratory focuses on chemical proteomics-enabled discovery of new cysteine-reactive small molec...
Covalent inactivation of proteins by small molecules is experiencing an increasing trend in pharmace...
In this thesis, we develop a new mass spectrometry-based chemoproteomic method that allows detection...
There is a resurging interest in compounds that engage their target through covalent interactions. C...
Despite recent clinical successes for irreversible drugs, potential toxicities mediated by unpredict...
Proteomic profiling using bioorthogonal chemical probes that selectively react with certain amino ac...
Cysteine‐reactive small molecules are used as chemical probes of biological systems and as medicines...
In this doctoral thesis, the focus lied on identifying the protein targets of different bioactive cy...
ABSTRACT: Significant resources in early drug discovery are spent unknowingly pursuing artifacts and...
The biomedical and pharmaceutical communities are experiencing a growing demand for new druggable ta...
While many disease-modifying protein targets have been discovered, most of these targets have remain...
Medical community and pharmaceutical companies are currently facing a dire need for discovery and id...
Most small-molecule probes and drugs alter cell circuitry by interacting with 1 or more proteins. A ...
Targeted covalent inhibitor design is gaining increasing interest and acceptance. A typical covalent...
Covalent inhibitors have numerous applications as drugs, as tools for drug discovery, and as probes ...
Our laboratory focuses on chemical proteomics-enabled discovery of new cysteine-reactive small molec...
Covalent inactivation of proteins by small molecules is experiencing an increasing trend in pharmace...
In this thesis, we develop a new mass spectrometry-based chemoproteomic method that allows detection...
There is a resurging interest in compounds that engage their target through covalent interactions. C...
Despite recent clinical successes for irreversible drugs, potential toxicities mediated by unpredict...
Proteomic profiling using bioorthogonal chemical probes that selectively react with certain amino ac...
Cysteine‐reactive small molecules are used as chemical probes of biological systems and as medicines...
In this doctoral thesis, the focus lied on identifying the protein targets of different bioactive cy...
ABSTRACT: Significant resources in early drug discovery are spent unknowingly pursuing artifacts and...
The biomedical and pharmaceutical communities are experiencing a growing demand for new druggable ta...
While many disease-modifying protein targets have been discovered, most of these targets have remain...
Medical community and pharmaceutical companies are currently facing a dire need for discovery and id...
Most small-molecule probes and drugs alter cell circuitry by interacting with 1 or more proteins. A ...
Targeted covalent inhibitor design is gaining increasing interest and acceptance. A typical covalent...